Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | MARK3 | P27448 | 1/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 6/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyladenine SCHEMBL152594 | 0.73 | LRRK2 (1.00) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| Dimethyladenine SCHEMBL29349831 | 0.73 | LRRK2 (1.00) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| Dimethyladenine SCHEMBL11157548 | 0.72 | PDPK1 (0.96) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL9047405 | 0.71 | ALDH1A1 (0.40) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL8583607 | 0.71 | PI4KA (0.53) | PDPK1LRRK2CDK2MAP3K5ALDH1A1 | |
| SCHEMBL545951 | 0.70 | PDPK1 (0.37) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL546075 | 0.70 | XDH (0.53) | CDK2HSD17B10HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9705707 | 0.69 | CDK2 (0.56) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL6747380 | 0.69 | CHEK1 (0.56) | PDPK1LRRK2CHEK1AURKACHEK2 | |
| SCHEMBL401117 | 0.69 | PDPK1 (0.59) | PDPK1LRRK2CHEK1AURKACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11015194-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | ALNYLAM PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005004794-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | PDPK1 4009/4885LRRK2 2027/4885CHEK1 2289/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PDPK1 2827/4885LRRK2 2155/4885CHEK1 1535/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | PDPK1 3389/4885LRRK2 3317/4885CHEK1 4530/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | PDPK1 2827/4885LRRK2 2155/4885CHEK1 1535/4885 |
| US-20050119214-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | PDPK1 3303/4885LRRK2 1696/4885CHEK1 1080/4885 |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | FANCI, PCNA, DNMT1 | PDPK1 4568/4885LRRK2 3817/4885CHEK1 1989/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PDPK1 2827/4885LRRK2 2155/4885CHEK1 1535/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | PDPK1 2395/4885LRRK2 2399/4885CHEK1 3471/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | PDPK1 2827/4885LRRK2 2155/4885CHEK1 1535/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | PDPK1 4540/4885LRRK2 3251/4885CHEK1 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.